Highest-materiality recent filing
ALX Oncology Q1 2026 net loss narrows to $17.9M; evorpacept data shows durable responses
GAAP net loss of $17.9M ($0.17/sh) vs $30.8M ($0.58/sh) YoY; R&D expenses down to $13.6M.
ALX Oncology Q4 GAAP net loss $22.8M ($0.42/sh), completes $150M offering, cash runway to 1H 2028
Cash $48.3M at Dec 31, 2025; after Feb 2026 $150M offering net $140.4M, runway through 1H 2028.
ALX reports $48.3M cash; CD47 predictive of evorpacept response in HER2+ breast cancer Phase 1b/2
Preliminary cash, cash equivalents, and investments total $48.3M as of Dec 31, 2025.
ALX Oncology prices ~$150M equity offering at $1.57/share; includes pre-funded warrants
Gross proceeds expected ~$150M from sale of 76,979,112 common shares at $1.57 and pre-funded warrants for 18,574,120 shares at $1.569.
GAAP net loss for Q3 2025 was $22.1M ($0.41/share), improved from $30.7M ($0.58/share) in Q3 2024.
Alan Sandler resigns as CMO effective Sep 26, 2025, returns to Board as director.
GAAP net loss of $25.9M ($0.49/share) vs $39.4M ($0.76) in Q2 2024; R&D expense down 48% to $18.0M.
ALX Oncology Reports Q1 2025 Financial Results, Updates on Evorpacept and ALX2004 Pipeline
Reported Q1 2025 net loss of $30.8M ($0.58 per share) compared to $35.6M in Q1 2024; cash runway extended into Q4 2026 with $107.0M in cash.
ALX Oncology receives Nasdaq bid price non-compliance notice; 180-day cure until Oct 20, 2025
Nasdaq notified ALXO on Apr 23, 2025 that its common stock failed to maintain $1.00 minimum bid price for 30 consecutive business days.
ALX Oncology Q4 net loss $29.2M; cash $131.3M; evorpacept data positive; workforce cut
GAAP net loss Q4 2024: ($29.2M) or ($0.55)/share, improved from ($45.5M) or ($0.93)/share in Q4 2023.
ALX Oncology reduces workforce by 30%; President and CSO Pons to depart April 2025
Board approved ~30% workforce reduction to prioritize pipeline and extend cash runway; substantially complete by May 2025.
ALX Oncology appoints Harish Shantharam as CFO and adds Klencke, Takimoto to board
Harish Shantharam named CFO effective Jan 21, 2025; base salary $490k, target bonus 40%, option for 600k shares.
ALX Oncology appoints Alan Sandler as CMO; CFO Garcia departs with separation agreement
Alan Sandler, M.D., appointed Chief Medical Officer effective Nov 10, 2024; base salary $575k, signing bonus $50k, 700k stock options.
ALX Oncology reports Q3 net loss $0.58/share; CFO Garcia resigns, Pinto interim
GAAP net loss $30.7M ($0.58 per share) vs $51.0M ($1.24) in Q3 2023; non-GAAP net loss $23.7M.
ALX Oncology CMO Sophia Randolph resigns; separation includes $503,880 and accelerated vesting
CMO Sophia Randolph resigns effective Oct 11, 2024; she leaves to pursue other professional opportunities.
ALX Oncology reports Q2 net loss $39.4M; ASPEN-06 gastric cancer data shows ORR 40.3% vs 26.6%
GAAP net loss $39.4M ($0.76/sh) vs $34.2M ($0.84/sh) in Q2 2023; non-GAAP net loss $32.1M.
ALX Oncology appoints Alan Sandler to Board; Pons and Randolph resign from Board
Alan Sandler, M.D., appointed to Board effective Aug 5, 2024; receives initial option for 40,400 shares vesting over 36 months.
ALX Oncology Q4 2023 net loss $45.5M; cash $218.1M; ASPEN-06 interim ORR 52%
GAAP net loss Q4 2023: $45.5M ($0.93/share); FY 2023 net loss $160.8M ($3.74/share).
the Company’s President and Chief Scientific Officer position will be eliminated effective in April 2025
Effective January 18, 2025, the Board appointed Barbara Klencke, M.D. to serve as a Class II director of the Board
Ms. Pinto resigned as the interim Chief Financial Officer effective as of the same date and will remain the Company’s Senior Vice President, Finance and Chief Accounting Officer and the principal accounting officer.
and Chris Takimoto, M.D., Ph.D., F.A.C.P., to serve as a Class III director of the Board
Effective January 21, 2025, the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) appointed Harish Shantharam to the office of Chief Financial Officer
Effective on the same date, Dr. Sandler resigned as a member of the Board and all committees thereof.
As previously disclosed, Peter Garcia resigned as Chief Financial Officer of the Company effective November 8, 2024, due to personal reasons.
On November 10, 2024, the Board of Directors (the “Board”) of ALX Oncology Holdings Inc. (the “Company”) appointed Alan Sandler, M.D., age 68, to the office of Chief Medical Officer to fill a recently created vacancy.
On November 5, 2024, Peter Garcia, Chief Financial Officer of the Company informed the Company of his resignation from his position effective November 8, 2024, due to personal reasons.
On November 7, 2024, the Board of Directors (the “Board”) of the Company appointed Shelly Pinto, the Company’s Senior Vice President, Finance and Chief Accounting Officer, as the Company’s interim Chief Financial Officer, effective upon Mr. Garcia’s resignation.
On September 30, 2024, Sophia Randolph, M.D., Ph.D., Chief Medical Officer of ALX Oncology Holdings Inc. (the “Company”) informed the Company of her resignation from her position effective October 11, 2024, to pursue other professional opportunities.
In addition, on August 5, 2024, Jaume Pons, Ph.D., and Sophia Randolph, M.D., Ph.D., resigned as members of the Company’s Board.
Max materiality 0.85 · Median 0.65 · Most common event earnings